News and Press Releases
Press releases
Theralase® Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
Press ReleaseTheralase® presented interim Phase II data showing Ruvidar™’s strong safety and efficacy in treating BCG-unresponsive bladder cancer, with durable complete responses, no serious drug-related adverse events, and potential for...
Theralase® Discovers New Mechanism of Action of Lead Drug
Press ReleaseTheralase® announces Ruvidar™ inhibits Deubiquitinating Enzymes (DUBs), a key factor in cancer and drug resistance. This dual action—blocking DUBs and inducing oxidative stress—makes Ruvidar™ a promising cancer therapy...
Theralase® Closes Non-Brokered Private Placement
Press ReleaseTheralase® closes $419,124 private placement financing by issuing 1,995,829 units at CAD 0.21 each, with warrants exercisable at CAD 0.32 for 5 years. Funds will support Phase II bladder cancer trials, HSV treatment R&D, Rutherrin®...
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Press ReleaseRuvidar™ (1%) showed superior efficacy in healing HSV-1 lesions in mice versus FDA-approved Acyclovir (5%) and Abreva (10%). Ruvidar™ requires fewer applications and works via novel electrostatic repulsion mechanisms...
Ruvidar Demonstrates 7 Year Complete Response
Press ReleaseA BCG-unresponsive bladder cancer patient achieved a 7-year complete response after one Ruvidar™ treatment activated by light. Theralase® plans regulatory submissions and expanded clinical trials in 2025–2026 for hard-to-treat...
Ruvidar Effective in the Treatment of Herpes
Press ReleaseRuvidar™ showed superior efficacy over Acyclovir and Abreva in treating HSV-1 in a mouse model. Theralase® plans topical formulation, toxicology, and Phase I/II trials pending funding in 2025....
Theralase® Releases 2024 Annual Financial Statements
Press ReleaseTheralase® reported a slight revenue decline in 2024 but reduced net loss, advanced clinical trials for cancer and Parkinson’s treatments, showed promising results in HSV and lymphoma studies, and plans FDA resubmissions....
Theralase® Closes Non-Brokered Private Placement
Press ReleaseTheralase® closed a non-brokered private placement, raising approximately CAD 310,200 by issuing 1,034,002 units at CAD 0.30 each. Proceeds will fund Phase II bladder cancer trials, Rutherrin® development, working capital, and general...
Theralase® Therapy Improves Motor and Non-Motor Function in Parkinson’s Patients
Press ReleaseTheralase®’s Cool Laser Therapy improved motor and non-motor functions in Parkinson’s patients in a triple-blind clinical study, showing enhanced cognition, neurovascular health, and movement, supporting its potential as a...
Theralase® Demonstrates Efficacy of Rutherrin® in Destruction of Non-Hodgkin’s Lymphoma
Press ReleaseTheralase® reported that Rutherrin®, combined with Metformin and radiation, eliminated Non-Hodgkin’s Lymphoma in an animal model. This trimodal therapy showed tumor regression and survival benefits, supporting its promise in treating...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.